NuGen Medical Devices has announced the expansion of its distribution network for the needle-free InsuJet injection device into Argentina, Chile, Costa Rica, and Peru.

This follows the placement of two additional sales orders by its distribution partner, Science-Link Trading SAPI de CV, which is also partnering with a large medical conglomerate to expand operations into big box retail pharmacies in Mexico.

Science-Link has placed orders for 500 units of InsuJet for March and 1,000 units for April 2024 to meet the growing demand in Mexico, a significant market for diabetes care.

NuGen’s agreement with Science-Link aims to sell around 5,000 units of InsuJet this year, but with the recent expansion, the company anticipates exceeding this target.

NuGen CEO Ian Heynen said: “We are delighted to report the sales progress, the big box opportunity and the expansion of the distribution network into Argentina, Chile, Costa Rica, and Peru of our partner Science-Link.”

The alliance between Science-Link and Conglomerate Medical, a network of more than 150 clinics and 1,500 medical consultants in Mexico, is expected to further increase InsuJet sales.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

This partnership plans to open ten new speciality clinics in Mexico, focusing on diabetes care and promoting the InsuJet device.

NuGen estimates the lifetime value of the 1,500 units sold to Science-Link to be approximately $1.35m, with the first delivery valued at $220,000 for the first quarter of 2024.

Science-Link CEO Juan Carlos Feregrino said: “In a very short time our team was trained by NuGen to sell and market the InsuJet and we placed and received our first order. Now, in 2024, we are ready for much larger opportunities in Mexico and Latin America as we look to improve life and the delivery of care for many who suffer with the daily burden of needles in the management of their diabetes.

“InsuJet delivers freedom to many who suffer bruising from routine injections and offers hope to those who fear needles and suffer needle phobia but still require daily injections – it’s a very real problem of very large proportions and at Science-Link are thrilled to be there to help.”